AM/PM dosing of LAMA for COPD: a randomized controlled trial protocol using digital recruitment and registries

RationaleLong-acting muscarinic antagonists (LAMAs) reduce the risk of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), usually taken once daily in the morning. However, the circadian activity of autonomic regulation suggests that the highest need for anticholinergic therapy ma...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Pradeesh Sivapalan, Valdemar Rømer, Tobias Wirenfeldt Klausen, Niklas Dyrby Johansen, Manan Pareek, Daniel Modin, Alexander Mathioudakis, Jørgen Vestbo, Josefin Eklöf, Alexander Jordan, John R. Hurst, Tor Biering-Sørensen, Jens-Ulrik Jensen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-08-01
Colecção:	Frontiers in Medicine
Assuntos:	long-acting muscarinic antagonists chronic obstructive pulmonary disease COPD exacerbation all-cause mortality intensive care admission
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fmed.2024.1430169/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!